
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
French drug maker Aventis agreed April 25 to accept a sweetened takeover offer from national rival Sanofi-Synth?labo.